# Maxwell Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maxwell-biosciences

- Industry: Biotechnology
- Headquarters: West Lake Hills, US
- Website: www.maxwellbiosciences.com
- Total disclosed funding: $11M
- Latest round: Seed (Oct 4, 2021)
- Investors on record: 4

## About

Based in Texas, US, and founded in 2016 by CEO Joshua McClure and Annelise Barron, Maxwell Biosciences, Inc. operates as a biotechnology company. In August 2025, Maxwell Biosciences, Inc. raised USD 20 million in venture funding from unspecified investors. The company develops a peptidomimetic drug platform CLAROMER™ that outputs low-molecular-weight compounds that are functionally distinct from macromolecules because of their ability to easily penetrate membranes. These compounds are designed to functionally imitate human peptides for the treatment of diseases including viruses, drug-resistant bacteria, biofilms, fungi, and cancers. The company has Oral and Inhaled development programs. The company will use the August 2025 funding for its research and development efforts and to expand its commercialization in other industries.

## Funding rounds

- Seed, Oct 4, 2021, $11M — Keiretsu Forum, DecentraNet, Star Lake Bioventures, Joseph Ventures

## Investors

- Keiretsu Forum — Seed
- DecentraNet (https://capitalatlas.ai/funds/decentranet) — Seed
- Star Lake Bioventures — Seed
- Joseph Ventures — Seed